...II study protocol submitted by BGC's subsidiary Provensis. The approval was granted after FDA reviewed Provensis'...

...on Varisolve due to concerns about the potential risks of gas embolism. BGC said its Provensis Ltd....
...studies as well as a clinical study to generate the information required by the FDA. Provensis...
...in January 2005. If positive, the second part of the study will be conducted and Provensis...

...BGC said its Provensis Ltd subsidiary plans to respond by November to an FDA clinical hold...

...held. CS First Boston is the underwriter. BGC will use the proceeds to fund its Provensis...